COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03798639
Recruitment Status : Recruiting
First Posted : January 10, 2019
Last Update Posted : October 21, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Joanne Jeter, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021